Home » Topics » BioWorld Science

BioWorld Science
RSS

Promising phase II results with APC-366

Oct. 4, 1996

Natural cAMP phosphodiesterase inhibitor reported by Nippon Kayaku

Oct. 4, 1996

Glaxo Wellcome decides not to develop oral asthma treatment

Oct. 4, 1996

Zeneca claims new antiasthma agents

Oct. 4, 1996

Schering-Plough seeks approval for corticosteroid nasal spray in rhinitis

Oct. 4, 1996

Calpain inhibitors from Fujirebio

Oct. 4, 1996

Astra NOS inhibitors as neuroprotectants

Oct. 4, 1996

Divalproex reduces cognitive deficits associated with lithium

Oct. 4, 1996

Genzyme-Diacrin joint venture for porcine neural cell products

Oct. 4, 1996

Spanish investigators report MAO inhibitors

Oct. 4, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...